The biotechnology industry is sending conflicting signals as we approach 2027. Some companies are expanding their workforces, while others are announcing significant layoffs, eliminating research programs or restructuring their operations.
For employers, the question is whether the industry's employment outlook is actually improving and what that means for recruiting in the coming year.
The latest figures suggest some improvement from 2025, although the available evidence does not support describing the biotechnology hiring market as having recovered.
According to BioSpace, 99 biopharmaceutical companies announced or planned layoffs affecting 19,538 employees through October 2026. During all of 2025, the publication tracked reductions affecting 43,242 employees across 200 companies.
That represents a substantial decline in reported layoffs, but October was a reminder of how unpredictable this industry remains. The number of employees affected by announced reductions increased 43% compared with October 2025.
At the same time, BioSpace reported that job postings on its platform increased 31% during the third quarter compared with the same period last year.
These figures are based on BioSpace's reporting and job listings rather than a complete census of biotechnology employment. They suggest improving conditions in parts of the industry, but they don't establish that hiring is recovering across the entire market.
Why biotech companies are still laying off employees
Biotechnology employment has always been closely connected to financing, clinical trial results, regulatory developments and the commercial prospects of individual products.
A company can have promising research and experienced employees but still face difficult decisions when financing becomes unavailable or a clinical program fails to meet expectations.
Several recent announcements illustrate the problem.
In October, Artiva Biotherapeutics announced plans to reduce its workforce by approximately 94% while exploring strategic alternatives. Caribou Biosciences also announced substantial layoffs after discontinuing development of its clinical-stage pipeline. EyePoint Pharmaceuticals announced a 53% workforce reduction following disappointing clinical results and a decision to concentrate resources on another development program.
These are different businesses facing different circumstances, but they demonstrate why biotechnology employment trends cannot be evaluated solely through industry-wide hiring figures.
For employees, these decisions can be devastating. For employers, they also change the availability of experienced professionals in certain therapeutic areas and technical disciplines.
What the layoffs mean for biotech recruiting in 2027
One consequence of the reductions is that some experienced biotechnology professionals who were previously employed are now available or considering their next opportunity.
That may benefit companies preparing to expand, particularly those with the financing and operational stability to move forward with hiring.
However, employers shouldn't assume that a larger number of available candidates makes every position easier to fill.
A company preparing for clinical trials may need professionals with specific experience in clinical development, regulatory affairs, quality or medical affairs. Another organization preparing for commercialization may be looking for sales leadership, market access expertise or executives who have successfully introduced products.
The experience required can vary considerably depending on the therapeutic area, development stage and size of the organization.
Through our work in specialized healthcare and life sciences recruiting, we've seen how narrowly defined experience requirements can affect the available candidate population.
There are positions where direct experience with a particular technology, regulatory process or clinical specialty is essential. There are others where someone from an adjacent life sciences business may bring the leadership and operational background needed to succeed.
Understanding that difference can expand the candidate population without compromising the requirements of the position.
Preparing for the next hiring cycle
For biotechnology employers developing their 2027 hiring plans, we recommend beginning with the company's upcoming business milestones.
A financing event, clinical trial expansion, regulatory submission or commercialization initiative can create a need for specialized professionals long before the organization is ready to make an offer.
Those hiring requirements should be considered alongside the company's financial position and the timing of its development plans.
The current employment environment also warrants a fresh look at compensation and candidate availability. Professionals affected by layoffs may be more accessible, but candidates with highly specialized experience will still evaluate the stability of a prospective employer, its leadership and the outlook for its products.
At AlediumHR, our life sciences recruiting services support specialized professional, management and executive searches. Our recruiters use Talentlytical®, our proprietary AI-powered sourcing platform, to identify potential candidates and evaluate their experience against the requirements of each assignment.
Biotechnology recruiting in 2027 is likely to remain highly dependent on the circumstances of individual companies. The reduction in reported layoffs is encouraging, but continued restructuring makes it premature to declare a broad recovery.
For employers preparing to hire, the more useful question is whether the organization has the financing, business priorities and recruiting strategy needed to attract the people who will help it reach its next milestone.
Organizations planning specialized life sciences or executive searches can contact AlediumHR to discuss their hiring requirements.